A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.

开始日期2025-09-30

申办/合作机构

Eli Lilly & Co.

NCT07153471

/ Recruiting临床3期

A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

开始日期2025-09-15

申办/合作机构

Eli Lilly & Co.

CTR20252895

/ Recruiting临床3期

在合并肥胖或超重的2型糖尿病参与者中评价orforglipron片剂每日一次给药相比安慰剂的有效性和安全性研究

研究GZP2 的目的是在合并超重或肥胖的T2D参与者接受 40 周治疗后比较 Orforglipron 与安慰剂对血糖控制的影响；此外，本研究还计划评估第 40 周直至 72 周治疗期间的体重减轻情况。

开始日期2025-08-07

申办/合作机构

礼来苏州制药有限公司

[+2]

100 项与奥格列龙相关的临床结果

登录后查看更多信息

100 项与奥格列龙相关的转化医学

登录后查看更多信息

100 项与奥格列龙相关的专利（医药）

登录后查看更多信息

项与奥格列龙相关的文献（医药）

2025-11-01·DIABETES OBESITY & METABOLISM

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes

Article

作者: Banerjee, Hiya ; Mather, Kieren J. ; Kazda, Christof ; Rosenstock, Julio ; Eyde, Sarah ; Robins, Deborah A. ; Konig, Manige ; Lin, Yanzhu ; Duffin, Kevin L. ; Wilson, Jonathan M.

Abstract:

Aims:

These participant‐level exploratory analyses evaluated the effects of orforglipron, a once‐daily, orally administered non‐peptide glucagon‐like peptide‐1 receptor agonist, versus dulaglutide and placebo, on β‐cell function and insulin sensitivity biomarkers.

Materials and Methods:

Participants (N = 378) in this 26‐week phase 2 study with inadequately controlled type 2 diabetes (T2D) were randomly assigned to orforglipron (3, 12, 24, 36, or 45 mg), dulaglutide (1.5 mg), or placebo. Treatment effects on β‐cell function and insulin sensitivity markers were assessed, including homeostatic model assessment indices of β‐cell function and insulin resistance (HOMA‐B and HOMA‐IR, respectively); fasting C‐peptide, insulin, serum glucose, and glucagon; adiponectin; insulin‐like growth factor binding protein 2; proinsulin; and the proinsulin/insulin ratio.

Results:

Orforglipron doses of 12 mg and higher were associated with improved β‐cell function and insulin sensitivity. HOMA‐B increased up to 123% (C‐peptide) and 132% (insulin) with orforglipron doses of 12 mg and higher from baseline to week 4 before stabilising. HOMA‐B increases were greater with all orforglipron doses than with dulaglutide. Additional β‐cell function biomarkers, such as fasting proinsulin and the proinsulin/insulin ratio, also improved with orforglipron doses of 12 mg and higher compared with baseline and to a greater extent than seen with dulaglutide. HOMA‐IR values decreased up to 16% (C‐peptide) and 23% (insulin) with orforglipron by week 26. Reductions in HOMA‐IR (insulin) were significant versus baseline only for the highest dose. IGFBP‐2 and adiponectin, corollary biomarkers of insulin sensitivity, were generally improved with orforglipron.

Conclusions:

Increased HOMA‐B and improved metabolic biomarkers suggest that treatment with the orally administered non‐peptide GLP‐1 receptor agonist orforglipron enhanced pancreatic β‐cell function and insulin sensitivity in patients with T2D.

2025-10-01·INTERNATIONAL JOURNAL OF OBESITY

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

Review

作者: Abenavoli, Ludovico ; Al Srouji, Nahlah ; Dumitrascu, Dan L ; Boitos, Irina ; Scarlata, Giuseppe Guido Maria ; Leucuta, Daniel-Corneliu ; Popa, Stefan-Lucian ; Ismaiel, Abdulrahman

Abstract:

Introduction:

Overweight and obesity are major global health issues, increasing disease risk and straining healthcare systems. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for weight loss but cause gastrointestinal side effects, affecting adherence. Research often focuses on diabetics, leaving a gap in understanding their effects on non-diabetic individuals with overweight or obesity. This systematic review and dose-response network meta-analysis addresses this gap, analyzing gastrointestinal adverse events from GLP-1 RAs in non-diabetic subjects with overweight or obesity.

Methods:

We evaluated available evidence by searching PubMed and EMBASE databases, according to specific inclusion and exclusion eligibility criteria to evaluate gastrointestinal adverse events associated with GLP-1 RAs in non-diabetic individuals with overweight or obesity. Quality assessment of included studies was conducted using Cochrane Collaboration’s tool.

Results:

Thirty-nine articles were included in the review showing a total number of 33,354 individuals. Nausea, vomiting, diarrhea, and constipation were the most common gastrointestinal adverse effects. All evaluated GLP-1 RAs led to a significant increase in nausea risk, with orforglipron showing the highest risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. Additionally, liraglutide, orforglipron, semaglutide, and tirzepatide were associated with increased vomiting risk, while cagrilinitide and exenatide showed no significant increase. Exenatide, cagrilinitide, orforglipron were not associated with diarrhea risk. Finally, semaglutide and liraglutide were associated to increased constipation risk, while cagrilinitide and exenatide showed no significant increase.

Conclusions:

GLP-1 RAs showed several adverse gastrointestinal effects in non-diabetic patients with overweight or obesity. Understanding the different risk profiles of GLP-1 RAs helps clinicians make informed treatment decisions by balancing therapeutic benefits with potential side effects.

2025-09-18·NEW ENGLAND JOURNAL OF MEDICINE

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Article

作者: Eyde, Sarah ; Denning, Max ; Fernández Landó, Laura ; Rosenstock, Julio ; Ludwig, Lisa ; Nevarez Ruiz, Luis ; Chen, Yanyun ; Liu, Rong ; Cox, David ; Li, Jianghao ; Hsia, Stanley ; Wu, Wen-Shuo

BACKGROUND:

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.

METHODS:

In this phase 3, double-blind, placebo-controlled trial, we randomly assigned participants in a 1:1:1:1 ratio to receive orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks. Participants had type 2 diabetes treated only with diet and exercise, a glycated hemoglobin level of at least 7.0% but no more than 9.5%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 23.0. The primary end point was the change from baseline to week 40 in the glycated hemoglobin level. A key secondary end point was the percent change in body weight from baseline to week 40.

RESULTS:

A total of 559 participants underwent randomization. The mean glycated hemoglobin level at baseline was 8.0%. At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 percentage points with the 12-mg dose, -1.48 percentage points with the 36-mg dose, and -0.41 percentage points with placebo. All three doses of orforglipron were superior to placebo with respect to the primary end point; the estimated mean difference from placebo was -0.83 percentage points (95% confidence interval [CI], -1.10 to -0.56) with the 3-mg dose, -1.06 percentage points (95% CI, -1.33 to -0.79) with the 12-mg dose, and -1.07 percentage points (95% CI, -1.33 to -0.81) with the 36-mg dose (P<0.001 for all comparisons). The mean glycated hemoglobin level at week 40 was 6.5 to 6.7% with orforglipron. The percent change in body weight from baseline to week 40 was -4.5% with the 3-mg dose, -5.8% with the 12-mg dose, -7.6% with the 36-mg dose, and -1.7% with placebo. The most common adverse events were mild-to-moderate gastrointestinal events, most of which occurred during dose escalation. No episodes of severe hypoglycemia were reported. Permanent discontinuation of orforglipron or placebo due to adverse events occurred in 4.4 to 7.8% of participants receiving orforglipron and 1.4% of participants receiving placebo.

CONCLUSIONS:

In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. (Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971940.).

494

项与奥格列龙相关的新闻（医药）

2025-10-18

·药时代

复星凯瑞获超6.5亿元A轮融资！

2025年10月17日，复星医药宣布其控股子公司复星凯瑞、复星医药产业（系复星凯瑞的直接控股股东）与深圳生物医药产业基金共同签订《增资协议》。深圳生物医药产业基金拟参与复星凯瑞A轮融资，即拟分期出资共计6亿元，认缴复星凯瑞不超过合计5.24亿元的新增注册资本。A轮融资所得款项将用于复星凯瑞及/或其子公司的运营和业务发展。复星凯瑞成立于2017 年4月，法定代表人为Wenjie Zhang。复星凯瑞主要从事细胞治疗产品的研发、生产和商业化。其首款CAR-T细胞治疗产品奕凯达（阿基仑赛注射液）为国内首个获批上市的CAR-T细胞治疗产品，目前该药品已获批治疗“既往接受二线或以上系统治疗后复发或难治性大B细胞淋巴瘤成人患者”在内的多个适应症。此外，目前复星凯瑞的第二款CAR-T细胞治疗产品FKC889的第一项适应症（用于治疗复发或难治性前体B细胞急性淋巴细胞白血病（ALL）成人患者）的药品注册申请已获国家药监局受理、第二项适应症（用于治疗既往接受过二线及以上治疗后复发或难治性套细胞淋巴瘤（r/r MCL）成人患者）于中国境内处于桥接临床试验阶段。本轮融资，还将获得复星凯瑞现任董事在内的14名核心管理层跟投，他们拟通过跟投平台共计出资352.5万元认缴复星凯瑞合计308.1070万元的新增注册资本。此举有效实现了核心团队与公司发展的长期利益绑定。为建立和完善长效激励约束机制，吸引和保留优秀人才，复星医药董事会及复星凯瑞股东会于同日分别批准复星凯瑞采纳并实施股权激励计划。根据该计划，复星凯瑞拟通过激励平台，以0.76元/1元注册资本的价格，分批向拟激励对象授出对应共计不超过9,321.9893万元注册资本的激励权益。本轮融资完成后，复星凯瑞的股权结构将出现变化。复星医药产业的持股比例将从88.14%降至69.50%，深圳生物医药产业基金将持股21.03%，成为继复星医药产业之后的第二大股东。增资完成后，复星凯瑞仍为复星医药的控股子公司。图片来源：即梦AI 头对头达格列净！礼来orforglipron两项三期研究报阳 2025-10-16 强生Q3营收亮眼，开启“断舍离”，分拆骨科业务 2025-10-15 恒瑞Newco公司获6亿美元B轮融资！ 2025-10-14 版权声明/免责声明本文为汇编文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩内容！

细胞疗法上市批准免疫疗法临床3期

2025-10-18

·药时代

礼来欲收购Nektar？？？

面对诉讼，一劳永逸的方式就是将原告买下。 10月17日，金融博客Betaville向其订阅者发送了与有关Nektar Therapeutics可能被礼来收购的市场预警。 Betaville是以一个专注于报道收并购的平台，此前曾放出“辉瑞有意收购Viking”、“Altimmune正与三家MNC进行并购谈判”等众多未经证实的劲爆消息。受此次收购消息影响，Nektar（NKTR）股价盘中大涨12%，截止收盘涨幅度收至5.11%，目前公司市值为10.99亿美元。目前，没有所谓的交易双方并未就此发布任何申明，这则消息仍属市场传闻和推测范畴。不过，近期关于Nektar的另一则消息颇为有趣，也与礼来有关：投行B. Riley表示，由于政府停摆，Nektar对礼来诉讼的审前听证会已从10月16日推迟至至少12月11日之后。两则看似不相关的消息，联系在一起却给人了带来不小的想象空间，不乏投资者热衷于吃瓜与乱点鸳鸯谱，就爱看些“欢喜冤家终结良缘”的烂俗剧情。 8年恩怨从一纸诉讼与礼来对簿公堂，到一则传言与礼来喜结连理，Nektar与礼来的恩恩怨怨已有8年之久。 2017年，礼来从Nektar手中引进了一款IL-2激动剂NKTR-358（Rezpeg），2023年，礼来以一期临床数据不佳为由退回了该产品权益。本来交易买卖退货，实属正常。但乌龙的是，Nektar拿回原数据找第三方评估发现，礼来数据分析有误。具体而言，包括两点：1.经过验证的72点-EASI（降低湿疹面积和严重程度指数）评分系统计算错误；2.排除了3例可分析的受试者。有趣的是，礼来负责临床研究的内部统计和临床团队面对Nektar的质问“供认不讳”，但也只是承认。这让Nektar更加气不过，一纸诉讼便将礼来告上了法庭。诉状中写道：“作为世界上最大的制药公司之一，礼来向其联合开发伙伴Nektar推卸了临床和契约性责任。” Nektar告礼来不仅仅是告他们“马虎”，更是告后者存在不当竞争。原来礼来2020年收购了一家名为Dermira的竞品公司。礼来通过收购该公司获得了一款IL-13抑制剂Ebglyss，并拥有该产品在欧洲以外的全球权益。 2023年，也就是Rezpeg被退货的这一年，欧盟委员会宣布批准Ebglyss用于AD治疗。紧接着2024年，该药又陆续在日本、美国上市。诉讼仍在进行，只是如今被推迟至12月之后…… 理性吃瓜当下的Nektar虽算不上“春风得意”，但日子确实好过了些。 2025年6月，Nektar公布了Rezpeg用于治疗特异性皮炎（AD）的IIb期研究数据。结果显示，不同剂量组358治疗16周后，EASI下降幅度分别为61%、58%、53%。而安慰剂组的下降幅度则为31%，各治疗组之间的均具有统计学差异。次要终点上，相比安慰剂组，第16周时，三个剂量组358的EASI-505（EASI评分较基线下降≥50%）、EASI-75（EASI评分较基线下降≥75%）、BSA（皮损累及体表面积评分）也达到了统计学差异。Nektar股价大涨156%。 9月18日，该IIb期研究数据更新，结果显示接受研究疗法超过16周的延长治疗的患者，临床效果得到深化，EASI绝对减少程度增强，并且经过24周的治疗后，EASI-75 和 vIGA 0/1 反应率更高。Nektar股价再涨15%。此外，今年Treg细胞得诺贝尔奖了，作为根正苗红的Treg概念股Nektar也因此受益，今年以来该公司股价上涨了294%。然而，这并非就代表礼来会出手收购Nektar。有业内人士分析，Rezpeg对比度普利尤单抗无疗效优势。见下表：图片来源：Antibody Research 从安全性上来看，Rezpeg也具有更高的停药率。对比活性药物，这样安全性与有效性均无明显优势的药物即便上市，商业化问题也不容忽视。那么，礼来收购Nektar的理由是什么？爱情吗？还是说，诉讼带来的“天价赔偿”够买一个Nektar？图片来源：即梦AI 头对头达格列净！礼来orforglipron两项三期研究报阳 2025-10-16 强生Q3营收亮眼，开启“断舍离”，分拆骨科业务 2025-10-15 恒瑞Newco公司获6亿美元B轮融资！ 2025-10-14 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩内容！

并购临床2期

2025-10-17

·PRNewswire

Weekly Recap: 14 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including updates in mental health, cancer awareness and the vital importance of washing your hands. NEW YORK, Oct. 17, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, Oct. 13-17, 2025. Hugel Inc. appoints Carrie Strom as Chief Executive Officer Carrie Strom is a 25-year pharmaceutical and aesthetics industry leader who previously served as Global President of Allergan Aesthetics. "My priority is to build on Hugel's leadership in South Korea and transform it into a global aesthetics powerhouse, raising the bar for how we serve customers and patients around the world," she said. Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint. Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics Waters Xevo CDMS delivers unmatched characterization for mega-mass biomolecules central to next-generation therapies. Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology Developed in collaboration with Eli Lilly and Company, this minimally invasive test provides clinicians with information that can help identify patients in early stages of cognitive decline who are unlikely to have Alzheimer's-related amyloid pathology. Global Handwashing Day 2025 Underscores the Power of Soap and Water to Save Lives Celebrated annually on October 15, this worldwide event reminds people that consistent hand hygiene is critical to preventing the spread of infectious diseases and protecting community health. Kohler Co. Launches Kohler Health, Ushering in a New Era of Health and Wellness in the Home As health and wellness continue to expand to the home setting, the bathroom stands as an untapped hub of vital health data and information. Every day, we flush away insights that could help us better understand our bodies and our health. Kohler Health is challenging people to re-imagine how they think about the bathroom. Friendship is Fitness: New Research From Peerspace Shows Social Connection as Key to Health Healthy social connection depends on getting the right mix of interactions that meet our individual social needs. Peerspace's new quiz introduces eight distinct social connection personality types – from The Deep Diver to The Silly Goose – each reflecting a unique way people experience and seek out connection. Clear Channel Outdoor and Blood Cancer United Team Up on Billboard Campaign to Reach More People Affected by Blood Cancer The out-of-home campaign introduces The Leukemia & Lymphoma Society's new name, Blood Cancer United, to engage more communities and increase awareness of blood cancer. Pink Aid Celebrates 15 Years of Compassion and Support for Breast Cancer Patients Facing Financial Crisis Created in 2011 by Amy Katz, Andrew Mitchell-Namdar, Renee Mandis, and Amy Gross, Pink Aid was born from a critical need: while treatments for breast cancer have advanced, one in three patients still faces financial collapse. Many lose their jobs, delay care, or risk eviction while battling for their lives. The founders envisioned a community of care to ensure patients never have to choose between treatment and basic necessities like food and shelter. 81% of Americans Say Mental Health Support Can't Wait - They Expect It Within Hours, New CallTrackingMetrics Report Finds The report paints a picture of a growing dilemma in access to behavioral health care: timeliness. When care is delayed, it's denied. One in five Americans said they reached out to mental health or addiction treatment providers for help, but never heard back. Twin Health and Peloton Partner to Transform Metabolic Health The unique partnership will bring Peloton's world-class fitness and wellness content to Twin's AI digital twin program, proven to treat diabetes, prediabetes and obesity while reducing reliance on medications. On World Mental Health Day, NAMI Announces New Scientific Advisory Council to Advance Hope Through Research The council unites leading scientists, clinicians, and advocates to ensure that cutting-edge research and lived experience together shape the future of mental health care. Trust and Transparency Rule: How Scientists Choose Antibodies in 2025 Drawing on feedback from hundreds of scientists, the 2025 report highlights evolving trends in antibody selection, purchasing behavior, and usage. Karmanos Shines a Green Light on Liver Cancer in October: Know the Risks, Know the Signs According to the American Cancer Society, more than 800,000 people are diagnosed with liver cancer around the world each year. Here in the U.S., over 42,200 new cases of liver cancer are estimated to occur in 2025. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果

100 项与奥格列龙相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
压力性尿失禁	临床3期	美国	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	中国	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	日本	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	加拿大	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	捷克	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	印度	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	墨西哥	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	波兰	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	罗马尼亚	Eli Lilly & Co.	2025-09-30
压力性尿失禁	临床3期	韩国	Eli Lilly & Co.	2025-09-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06045221 (ACHIEVE-3, PRNewswire) 人工标引	临床3期	2型糖尿病	1,698	orforglipron 12 mg	繭糧觸蓋糧構築簾淵壓(鹹製壓繭範蓋廠憲窪簾) = 鹹築齋蓋廠構積餘構憲鹽獵衊觸鑰鹽顧範齋獵 (憲壓遞築糧觸遞衊艱遞 ) 达到更多	优效	2025-09-17
				orforglipron 36 mg	繭糧觸蓋糧構築簾淵壓(鹹製壓繭範蓋廠憲窪簾) = 膚鬱觸獵鬱願膚鹹醖醖鹽獵衊觸鑰鹽顧範齋獵 (憲壓遞築糧觸遞衊艱遞 ) 达到更多
NCT05869903 (ATTAIN-1, Company_Website \| N Engl J Med) 人工标引	临床3期	肥胖	-	Orforglipron 6 mg	蓋選糧鹹顧襯淵範鏇夢(願艱網襯顧衊窪鹽夢願) = 選積獵觸襯製鑰夢積夢鹹餘選蓋衊艱憲選鑰選 (夢積蓋壓鹹範構願艱壓 ) 达到更多	积极	2025-09-16
				Orforglipron 12 mg	蓋選糧鹹顧襯淵範鏇夢(願艱網襯顧衊窪鹽夢願) = 願襯齋壓鏇鹹醖蓋糧壓鹹餘選蓋衊艱憲選鑰選 (夢積蓋壓鹹範構願艱壓 ) 达到更多
NCT05872620 (ATTAIN-2, Company_Website) 人工标引	临床3期	2型糖尿病 \| 超重 \| 肥胖	-	Orforglipron 6 mg	糧觸築窪鹽鬱鑰齋顧衊(醖廠築鑰窪鬱選膚窪鹹) = 壓壓艱鬱遞糧製觸憲網醖鬱餘觸衊艱繭鏇蓋構 (壓築獵鹹糧築蓋鑰膚簾 ) 更多	积极	2025-08-26
				Orforglipron 12 mg	糧觸築窪鹽鬱鑰齋顧衊(醖廠築鑰窪鬱選膚窪鹹) = 鑰壓積鹹餘窪艱壓鏇鏇醖鬱餘觸衊艱繭鏇蓋構 (壓築獵鹹糧築蓋鑰膚簾 ) 更多
NCT05869903 (ATTAIN-1, NEWS) 人工标引	临床3期	超重 \| 肥胖	-	orforglipron	壓範範廠膚膚製繭構簾(糧窪鏇獵顧願艱廠顧獵) = orforglipron的三个剂量组与安慰剂组相比均达到了主要终点廠壓鑰淵願遞鏇醖餘壓 (選網糧齋範醖鹹艱醖築 ) 达到更多	积极	2025-08-07
				安慰剂
NCT05971940 (ACHIEVE-1, Pubmed \| N Engl J Med) 人工标引	临床3期	2型糖尿病	559	Orforglipron 3 mg	構窪鬱淵範鏇鏇餘壓繭(壓繭網繭範齋壓鬱選遞) = 憲繭鬱糧鬱顧鏇獵繭鹹範積製壓蓋網簾廠積鹹 (鹹淵襯製蓋衊製艱襯顧 ) 更多	积极	2025-06-21
				Orforglipron 12 mg	構窪鬱淵範鏇鏇餘壓繭(壓繭網繭範齋壓鬱選遞) = 簾淵鹽廠選積餘鑰齋鏇範積製壓蓋網簾廠積鹹 (鹹淵襯製蓋衊製艱襯顧 ) 更多
NCT05971940 (ACHIEVE-1, Biospace \| NEWS) 人工标引	临床3期	2型糖尿病	559	Orforglipron 3 mgOrforglipron 3 mg	構膚醖蓋齋淵築積顧膚(鏇製廠繭鏇淵衊夢憲壓) = 淵遞憲鏇範衊餘憲襯壓鏇鏇選廠鏇構憲積願糧 (遞範夢鏇簾憲範淵糧鬱 ) 达到更多	积极	2025-04-17
				OrforglipronOrforglipron 12 mg	構膚醖蓋齋淵築積顧膚(鏇製廠繭鏇淵衊夢憲壓) = 壓鏇獵膚憲蓋憲鹹築願鏇鏇選廠鏇構憲積願糧 (遞範夢鏇簾憲範淵糧鬱 ) 达到更多
NCT05051579 (EASD2023)	临床2期	超重 \| 肥胖	272	Orforglipron (OFG) 12 mg	廠構窪淵範鑰廠夢糧積(膚齋醖繭顧網顧廠糧積) = 醖獵範夢顧顧膚襯鏇淵鏇遞餘網衊觸襯築夢繭 (淵積襯積廠鏇膚鑰鬱衊 ) 更多	积极	2023-10-03
				Orforglipron (OFG) 24 mg	廠構窪淵範鑰廠夢糧積(膚齋醖繭顧網顧廠糧積) = 獵夢糧鏇範獵選壓齋遞鏇遞餘網衊觸襯築夢繭 (淵積襯積廠鏇膚鑰鬱衊 ) 更多
NCT05051579 (GZGI, CTgov)	临床2期	肥胖	272	LY3502970 (24 mg LY3502970)	淵築繭繭選蓋廠餘窪獵(夢醖鏇鑰窪構鹹膚製繭) = 築鹹網鏇繭糧願鬱積鹽襯繭顧鹽積獵網鑰憲夢 (網顧夢蓋壓顧鬱鬱夢鬱, 0.82) 更多	-	2023-09-13
				Placebo (Placebo)	淵築繭繭選蓋廠餘窪獵(夢醖鏇鑰窪構鹹膚製繭) = 餘顧鏇齋鑰獵膚憲鹽鏇襯繭顧鹽積獵網鑰憲夢 (網顧夢蓋壓顧鬱鬱夢鬱, 0.81) 更多
NCT05048719 (ADA 12023 \| ADA 22023) 人工标引	临床2期	2型糖尿病	383	Orforglipron 3 mg	壓齋製鏇餘繭鏇蓋構觸(憲艱餘積餘膚窪鑰膚艱) = 糧網淵齋顧糧製窪遞獵夢窪網鬱構選鏇壓獵遞 (鬱蓋蓋範齋壓淵鹽鏇鹽 ) 更多	积极	2023-06-25
				Orforglipron 12 mg	壓齋製鏇餘繭鏇蓋構觸(憲艱餘積餘膚窪鑰膚艱) = 艱願製顧窪鹽壓願窪襯夢窪網鬱構選鏇壓獵遞 (鬱蓋蓋範齋壓淵鹽鏇鹽 ) 更多
NCT05048719 (Literature \| Pubmed \| Lancet) 人工标引	临床2期	2型糖尿病	303	orforglipron	選鏇製夢遞繭鑰蓋醖夢(獵鏇鬱製顧鹽艱觸淵蓋) = 襯遞顧鬱糧窪壓餘鏇願願網鏇艱壓窪顧簾製壓 (遞膚願鏇窪淵範蓋艱簾 ) 更多	积极	2023-06-23
				Dulaglutide	選鏇製夢遞繭鑰蓋醖夢(獵鏇鬱製顧鹽艱觸淵蓋) = 蓋獵願衊淵簾膚顧顧構願網鏇艱壓窪顧簾製壓 (遞膚願鏇窪淵範蓋艱簾 ) 更多